ANGPT2 Knockout Cell Line (HEK 293)

The choice depends on whether you are studying ANGPT2 (angiopoietin-2)'s role as the principal Tie2 ligand antagonist or modeling angiogenesis and emerging anti-angiogenic therapy. The Knockout line is the standard tool for asking whether ANGPT2 is required for these processes — ANGPT2 is a secreted growth factor that binds Tie2 (TEK) receptor on endothelial cells with similar affinity to ANGPT1 but functions as a context-dependent agonist/antagonist; ANGPT2 destabilizes endothelial junctions, promotes vascular remodeling, and is critical for pathological angiogenesis in cancer and diabetic retinopathy/age-related macular degeneration (AMD). Overexpression is useful for studying ANGPT2 gain-of-function effects. For angiogenesis and vascular biology research, the EDITGENE ANGPT2 Knockout in HEK293 is uniquely valuable — HEK293 supports systematic structure-function studies. Rescue with wild-type ANGPT2 is the standard specificity control. The knockout is a critical specificity tool for ⭐⭐ faricimab (Vabysmo, FDA-approved 2022, anti-Ang2 × anti-VEGF bispecific antibody for neovascular AMD and diabetic macular edema), ⭐ nesvacumab (anti-Ang2 antibody), trebananib (Ang1/2-binding peptibody), and emerging Ang2-Tie2 axis-targeted therapeutics in cancer and retinal vascular diseases — Ang2 has emerged as a key target alongside VEGF for retinal vascular diseases.

Primary applications: • Anti-Ang2 therapy specificity: critical genetic control for ⭐⭐ faricimab (Vabysmo) — should have no anti-Ang2 binding activity in ANGPT2-null cells. • Tie2-ANG axis: ANGPT2-Tie2 binding analysis and competition with ANGPT1. • Endothelial junction biology: in heterologous endothelial contexts, ANGPT2's role in vascular destabilization. • Cancer angiogenesis: emerging anti-Ang2-targeted cancer therapy specificity testing. EDITGENE recommends this model as a critical specificity control for the emerging Ang2-Tie2 axis-targeted retinal disease and cancer drug development field.

Yes. ANGPT2 rescue experiments require attention to secreted growth factor architecture: • Construct design: use a codon-modified ANGPT2 sequence with a small N-terminal tag (FLAG, HA, after signal peptide). ANGPT2 has signal peptide, coiled-coil oligomerization domain, and C-terminal fibrinogen-like Tie2-binding domain — preserve all elements. • Secretion validation: confirm conditioned media ANGPT2 secretion by ELISA. • Tie2-binding-deficient rescue: fibrinogen-like domain mutations disrupt Tie2 binding. • Functional readout: rescue should restore ANGPT2-induced Tie2 destabilization and faricimab binding. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.